Evolent Health (NYSE:EVH) Shares Cross Below 200 Day Moving Average - Time to Sell?

Key Points

• Evolent Health shares fell below their 200-day moving average, trading as low as $3.61 versus the $3.72 average, signaling technical weakness.
• The company posted adjusted earnings of $0.02 per share, beating expectations, while revenue increased 46.9% year over year. Management guided for approximately $2.6 billion to $2.7 billion in 2026 revenue, above consensus.
• Analysts maintain a “Moderate Buy” consensus with a $6.16 price target, but Evolent remains GAAP-unprofitable and highly leveraged, with a debt-to-equity ratio of 2.46 and projected full-year losses.

Evolent Health, Inc (NYSE:EVH - Get Free Report) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.72 and traded as low as $3.61. Evolent Health shares last traded at $3.9580, with a volume of 5,080,277 shares trading hands.

Evolent Health News Roundup

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Evolent reported second-quarter adjusted earnings of $0.02 per share, compared with analysts’ expectation of a $0.01 loss and a $0.10 loss in the year-ago quarter. Evolent Health Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Quarterly revenue rose sharply year over year, with management emphasizing continued growth, improving profitability, and stronger cash flow. The earnings call also highlighted a bullish 2027 outlook, supporting the view that Evolent’s expansion is becoming more durable. Evolent Health Q2 2026 Earnings Call Highlights
• Positive Sentiment: The company raised or reaffirmed full-year 2026 revenue guidance at approximately $2.6 billion to $2.7 billion, above the roughly $2.5 billion consensus estimate. That outlook gives investors greater confidence in Evolent’s growth trajectory. Evolent Announces Second Quarter 2026 Results
• Neutral Sentiment: Despite the improved operating performance, Evolent remains unprofitable on a GAAP basis, with a negative net margin, and analysts still project a full-year loss. Execution against the new guidance will therefore remain important.
• Negative Sentiment: The company continues to carry elevated leverage, including a debt-to-equity ratio above 2, which could limit financial flexibility if growth or cash-flow improvements fall short.

Analyst Ratings Changes

A number of research analysts recently commented on EVH shares. Needham & Company LLC upped their target price on Evolent Health from $4.00 to $5.00 and gave the company a "buy" rating in a research note on Thursday, May 7th. Canaccord Genuity Group lifted their price target on shares of Evolent Health from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Tuesday, July 21st. Truist Financial lowered shares of Evolent Health from a "buy" rating to a "hold" rating and set a $7.00 price target on the stock. in a report on Tuesday, June 30th. Citigroup restated a "sell" rating and issued a $6.75 price objective (up from $5.50) on shares of Evolent Health in a research note on Thursday, July 23rd. Finally, TD Cowen reduced their price objective on shares of Evolent Health from $8.00 to $5.00 and set a "buy" rating for the company in a report on Tuesday, July 28th. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Evolent Health has a consensus rating of "Moderate Buy" and a consensus price target of $6.16.

Evolent Health Stock Performance

The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 2.46. The firm has a market capitalization of $445.20 million, a price-to-earnings ratio of -0.87 and a beta of 0.79. The stock has a fifty day moving average price of $4.75 and a 200-day moving average price of $3.72.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The technology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. Evolent Health had a negative return on equity of 3.94% and a negative net margin of 24.08%.The business had revenue of $484.50 million for the quarter, compared to analyst estimates of $597.69 million. During the same quarter in the previous year, the firm earned ($0.10) EPS. Evolent Health's quarterly revenue was up 46.9% on a year-over-year basis. As a group, analysts anticipate that Evolent Health, Inc will post -0.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Evolent Health

Several large investors have recently made changes to their positions in EVH. Brighton Jones LLC acquired a new position in Evolent Health in the fourth quarter valued at about $3,927,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Evolent Health by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company's stock worth $1,217,000 after buying an additional 3,572 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Evolent Health by 162.2% during the first quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company's stock worth $26,861,000 after buying an additional 1,754,520 shares in the last quarter. Caxton Associates LLP bought a new position in shares of Evolent Health in the first quarter valued at approximately $252,000. Finally, Strs Ohio acquired a new position in shares of Evolent Health in the 1st quarter worth approximately $47,000.

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company's core offerings include care management solutions, population health analytics and clinical advisory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source